{"organizations": [], "uuid": "dc635614023cc33e334ba5f4ec4ebeaaa873d971", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180227.html", "section_title": "Archive News &amp; Video for Tuesday, 27 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-precision-therapeutics-forms-tumor/brief-precision-therapeutics-forms-tumorgenesis-subsidiary-idUSFWN1QH11P", "country": "US", "domain_rank": 408, "title": "BRIEF-Precision Therapeutics Forms Tumorgenesis Subsidiary", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-02-27T21:44:00.000+02:00", "replies_count": 0, "uuid": "dc635614023cc33e334ba5f4ec4ebeaaa873d971"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-precision-therapeutics-forms-tumor/brief-precision-therapeutics-forms-tumorgenesis-subsidiary-idUSFWN1QH11P", "ord_in_thread": 0, "title": "BRIEF-Precision Therapeutics Forms Tumorgenesis Subsidiary", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 27 (Reuters) - Precision Therapeutics Inc:\n* PRECISION THERAPEUTICS FORMS TUMORGENESIS INC. SUBSIDIARY TO FOCUS ON THE NEXT GENERATION OF PATIENT DERIVED TUMOR MODELS\n* ‍FORMED TUMORGENESIS TO DEVELOP A NEW, RAPID APPROACH TO GROWING TUMORS IN LABORATORY​\n* ‍TESTING OF TUMORGENESIS PDX TUMORS TO TAKE PLACE IN COLLABORATION WITH HELOMICS, IN WHICH CO HAS 20% EQUITY STAKE​\n* IN NEGOTIATIONS WITH MEDICAL TECHNOLOGY COS TO LICENSE THEIR TECHNOLOGY TO ADVANCE TUMORGENESIS‘S STRATEGIC PLAN​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-27T21:44:00.000+02:00", "crawled": "2018-02-28T12:56:15.001+02:00", "highlightTitle": ""}